Execitalopram oxalate tablets, a class 3.1 antidepressant drug of Kangenbei, was approved for production

According to the latest information on the website of the State Food and drug administration, acecitalopram oxalate, a 3.1 antidepressant drug of Kangenbei pharmaceutical, has been approved for production The drug is a first-line antidepressant widely used in the world, with a total sales volume of more than 100 million yuan in China last year Kangenbei's approved production of new spiritual drugs can enrich the company's existing product line and play a positive role in future performance Kangenbei is one of the leading enterprises of modern Chinese medicine It has established a complete product echelon and brand advantages in the two fields of cardiovascular and cerebrovascular system medicine and urinary system medicine At the same time, it has brand-name products and strong market competitiveness in the fields of digestion, anti infection and other disease treatment The sales of seven varieties, including QianLieKang and Changyanning, exceed 100 million This year, many varieties of the company were selected into the national base drug catalog and local supplement catalog, among which Tianbaoning ginkgo leaf capsule, omeprazole injection, tamoxin sustained-release capsule were selected into the national new base drug catalog, shexiangtongxin dropping pills were added into the base drug catalog of Guangdong Province and the new agricultural cooperation catalog of Fujian Province, and yanyanning was selected into the supplement base drug catalog of Qinghai Province The company's net profit in the first three quarters of this year increased 70% year on year Original research information of escitalopram oxalate tablets > > Product Name: general name of Laishi: escitalopram oxalate tablets English Name: escitalopram oxalate tablets [ingredients] escitalopram oxalate [properties] elliptical, white film coated tablets Indications 1 Treatment of severe depression (MDD): the major symptoms of MDD are significant or persistent depression or restlessness (at least for 2 weeks), mainly including the following symptoms: depression, loss of interest, significant changes in weight or appetite, insomnia or drowsiness, psychomotor arousal or retardation, excessive fatigue, guilt or inferiority complex, slow thinking or inattention, suicide An attempt or an idea 2 Generalized anxiety (GAD): excessive anxiety and worry, lasting for at least 6 months There are mainly the following symptoms: restlessness, fatigue, inattention, excitement, muscle tension and sleep disorders [Specification] 10mg [usage and dosage] 1 Severe depression: the initial dosage is 10mg once a day, which can be increased to 20mg once a day after a week, and taken orally in the morning or at night In general, the treatment should last several months or even longer 10 mg once a day is recommended for elderly patients or patients with liver dysfunction There is no need to adjust the dosage for mild or moderate renal dysfunction Use with caution in severe renal insufficiency 2 Generalized anxiety: the initial dose is 10mg once a day, which can be increased to 20mg once a day after a week, and taken orally in the morning or at night At least 14 days after the monoamine oxidase inhibitor (MAOI) is stopped, the drug can be replaced Similarly, the monoamine oxidase inhibitor can be used 14 days after the drug is stopped The dosage should be reduced gradually [adverse reactions] about 5% of the patients have insomnia, impotence, nausea, constipation, hyperhidrosis, dry mouth, fatigue and drowsiness About 2% of patients have headache, upper respiratory tract infection, back pain, pharyngitis and anxiety Occasionally, it can cause mania or mild mania or hyponatremia Patients with a history of convulsion should use it with caution There was no significant change in laboratory parameters There was no obvious abnormality in ECG [contraindications] please refer to the manual [note] for patients with liver and kidney dysfunction, with convulsion history or heart disease, thyroid disease, electrolyte disorder, other mental diseases (such as bipolar disorder) or suicidal thoughts, it should be used with caution During the period of taking medicine, it is not suitable to operate the machine Pregnant women or lactating women should use it with caution There is no clinical data on the safety of infants Patients allergic to this product or cetylpram should not be allowed [drug interaction] it is forbidden to use monoamine oxidase inhibitor in combination with alcohol and central nervous system drugs (such as antidepressants) with caution When combined with aspirin, warfarin and other anticoagulants, it may cause upper gastrointestinal bleeding Lithium salt may increase the effect of execetylpram, and should be used with caution Carbamazepine, an enzyme inducer, may increase the metabolism of escitalopram The combination of metoprolol and metoprolol had no significant effect on blood pressure and heart rate Execitalopram should not be used in combination with execitalopram [pharmacological action] escitalopram can enhance the function of 5-hydroxytryptamine (5-HT) in central nervous system, inhibit the reuptake of 5-HT, and is used in the treatment of depression Animal studies have shown that escitalopram is a selective 5-hydroxytryptamine reuptake inhibitor (SSRI), but has a weak reuptake effect on noradrenaline and dopamine, which is 100 times of the effect of the right-handed enantiomer of escitalopram Escitalopram has no or very little effect on 5-hydroxytryptamine 1-7 receptor or other receptors including α and β adrenergic, dopamine 1-5, histamine 1, muscarinic 1-5 and benzodiazepine receptor, and no effect on Na +, K +, Cl - and Ca + + ion channels [storage] sealed [package] 10 mg x 7 tablets 10 mg x 7 tablets / box 10 mg * 7 tablets 10 mg * 7 tablets 10 mg, 7 tablets / box 10 mg × 7 tablets [expiry date] three years [approval No.] gyzz j20100165 [approval date] 2010-12-10 0:00 [production enterprise] company name: Xi'an YANGSEN Pharmaceutical Co., Ltd production address: ottiliavej 9 dk-2500 valby Copenhagen